NCT04214197 - Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

February 3, 2020

Primary Completion Date

July 31, 2021

Study Completion Date

August 31, 2021

Conditions

Atopic Dermatitis

Interventions

DRUG

Crisaborole 2% Top Oint

Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.

Trial Locations (1)

02114

MGH Clinical Unit for Research Trials in Skin (CURTIS), Boston